Conference Book (PDF)

ESH eLearning, Faculty / Presenters, 417409

US, others

ESH eLearning, Guillermo Garcia-Manero, 412598

German, EMSCO, Italian

ESH eLearning, Faculty / Presenters, 412597

French, Spanish

ESH eLearning, Faculty / Presenters, 412596

Allogeneic HSCT in aged patients

ESH eLearning, Didier Blaise, 412595

Allo HSCT in patients with MDS

ESH eLearning, Didier Blaise, 412594

Response criteria for HR myelodysplastic syndromes

ESH eLearning, Amer Zeidan, 412592

Hypomethylating agent combinations

ESH eLearning, Mikkael Sekeres, 412591

HMAs -- a party of one

ESH eLearning, Guillermo Garcia-Manero, 412590

Pitfalls of response assessment in MDS

ESH eLearning, Mikkael Sekeres, 412589

Defining and treating relapsed/refractory lower-risk myelodysplastic syndromes

ESH eLearning, Valeria Santini, 412588

Standards for managing anemia

ESH eLearning, Eva Hellström- Lindberg, 412587

Frailty in MDS Patients

ESH eLearning, Rena Buckstein, 412586

A role for mature cells of the leukemic clone in chronic myelomonocytic leukemia

ESH eLearning, Dorothée Selimoglu-Buet, 412585

Myelodysplastic syndrome with SF3B1 gene mutation

ESH eLearning, Michaela Fontenay, 412584

The many faces of TP53

ESH eLearning, Claudia Haferlach, 412583

Comparing prognostic schemas

ESH eLearning, Torsten Haferlach, 412582

AI/ML to predict myelodysplastic syndromes response to drugs

ESH eLearning, Jaroslaw Maciejewski, 412581

AI/ML to diagnose myelodysplastic syndromes

ESH eLearning, Carsten Marr, 412579

WHO v. ICC

ESH eLearning, Lionel Adès, 412578

Diagnosing myelodysplastic syndromes: NGS

ESH eLearning, Klaus Metzeler, 412577

Diagnosing myelodysplastic syndromes: Classical tools

ESH eLearning, Aristoteles Giagounidis, 412576

The immunome

ESH eLearning, Shahram Kordasti, 412573

Therapy related myelodysplastic syndromes

ESH eLearning, Jean-Baptiste Micol, 412572

Germline mutations

ESH eLearning, Marie Sébert, 412571

Clonal haematopoiesis

ESH eLearning, Katharina Götze, 412569

Conference Book (PDF)

ESH eLearning, Faculty / Presenters, 412555

Closing Remarks

ESH eLearning, Faculty / Presenters, 411414

Panel discussion

ESH eLearning, Faculty / Presenters, 411413

NK CAR

ESH eLearning, Rafet Basar, 411411

Is there hope for PI3K inhibitors?

ESH eLearning, Jennifer Brown, 411410

PKC beta

ESH eLearning, James Blachly, 411409

Discussion

ESH eLearning, Faculty / Presenters, 411408

CAR-T cell immunotherapy for CLL

ESH eLearning, Tanya Siddiqi, 411407

Bispecific antibodies for CLL

ESH eLearning, Arnon Kater, 411406

Beyond venetoclax: other BH3 mimetic therapies

ESH eLearning, Matthew Davids, 411405

Panel discussion

ESH eLearning, Faculty / Presenters, 411404

Resistance to non-covalent BTK inhibitors

ESH eLearning, Jennifer Brown, 411401

Resistance to covalent BTK inhibitors

ESH eLearning, Jennifer Woyach, 411400

Panel discussion

ESH eLearning, Faculty / Presenters, 411399

What role will non-covalent BTK inhibitors play?

ESH eLearning, William Wierda, 411398

Choosing a covalent BTK inhibitor

ESH eLearning, Richard Furman, 411397

Satellite Symposium: New avenues to improving outcomes for CLL patients

ESH eLearning, Faculty / Presenters, 411396

Panel discussion

ESH eLearning, Faculty / Presenters, 411395

Defined duration vs MRD driven time-limited therapy

ESH eLearning, William Wierda, 411394

BTK - BCL-2 combinations

ESH eLearning, Carsten Niemann, 411393

Venetoclax antibody combinations

ESH eLearning, Barbara Eichhorst, 411392

Discussion

ESH eLearning, Faculty / Presenters, 411391

Preclinical rationale for combining bispecific antibodies with targeted therapy for CLL

ESH eLearning, Adrian Wiestner, 411390

Antitumor immunity in the lymphoid microenvironment

ESH eLearning, Martina Seiffert, 411387

Panel discussion

ESH eLearning, Faculty / Presenters, 411386

MRD: How do we measure it? Should NGS become the standard?

ESH eLearning, Andrew Rawstron, 411385

Genomic complexity by NGS, how does it relate to karyotype?

ESH eLearning, Pauline Robbe, 411384

Are del(17p) with concurrent TP53 mutation and isolated TP53 mutation really equivalent?

ESH eLearning, Sarka Pospisilova, 411383

Panel discussion

ESH eLearning, Faculty / Presenters, 411382

Therapy of Richter Transformation

ESH eLearning, Toby Eyre, 411381

Genomics of Richter’s; are the seeds of RS present at diagnosis?

ESH eLearning, Elias Campo, 411380

Modeling Richter’s Syndrome

ESH eLearning, Elisa Ten Hacken, 411379

Panel discussion

ESH eLearning, Faculty / Presenters, 411378

Genetic evolution of CLL under therapeutic selection

ESH eLearning, Justin Taylor, 411377

Focusing on stereotyped B cell receptors in CLL

ESH eLearning, Kostas Stamatopoulos, 411376

Mutated and unmutated IGVH CLL: two different diseases? Why do they respond differently to therapies?

ESH eLearning, Paolo Ghia, 411375

Is Low Count MBL a Precursor to CLL?

ESH eLearning, Susan Slager, 411374

Welcome words

ESH eLearning, Faculty / Presenters, 411373

Conference Book (PDF)

ESH eLearning, Faculty / Presenters, 411350

Closing Remarks

ESH eLearning, Faculty / Presenters, 411238

Panel discussion

ESH eLearning, Faculty / Presenters, 411237

Case-based lecture: Steroid-refractory GVHD

ESH eLearning, Daniel Wolff, 411236

Case-based lecture: Relapse post allo HCT

ESH eLearning, Jordi Esteve, 411235

Case-based lecture: Therapy related ALL

ESH eLearning, Caner Saygin, 411234

Interactive case: First R/R AML in fit AML

ESH eLearning, Judith Schaffrath, 411233

Conference Book (PDF)

ESH eLearning, Faculty / Presenters, 411190

Panel discussion

ESH eLearning, Faculty / Presenters, 411232

Case-based lecture: Red flags for germline predisposition

ESH eLearning, Marc Raaijmakers, 411231

Case-based lecture: Controversies around donor selection and CHIP

ESH eLearning, Michael Drazer, 411230

Case-based lecture: Clonal cytopenia of unknown significance (CCUS)

ESH eLearning, Gerwin Huls, 411229

Case-based lecture: BH3 mimetics in ALL

ESH eLearning, Kristen O’Dwyer, 411201

Discussion

ESH eLearning, Faculty / Presenters, 411227

CON

ESH eLearning, Yves Chalandon, 411226

PRO

ESH eLearning, Sabina Chiaretti, 411225

Introduction

ESH eLearning, Hervé Dombret, 411224

Discussion

ESH eLearning, Faculty / Presenters, 411223

Intensive chemo

ESH eLearning, Agnieszka Wierzbowska, 411222

VenAza as first line treatment before allo

ESH eLearning, Keith Pratz, 411221

Panel discussion

ESH eLearning, Faculty / Presenters, 411220

Case-based lecture: Novel antibody and CAR-T-Cell approaches in ALL

ESH eLearning, Lori Muffly, 411219

Case-based lecture: Is antibody targeting sufficient therapy for older adults with B-ALL?

ESH eLearning, Matthew J. Wieduwilt, 411217

Interactive case: The challenge to immune targeting of AML

ESH eLearning, Marion Subklewe, 411216

Discussion

ESH eLearning, Faculty / Presenters, 411215

Real world derived control arm vs experimental arm

ESH eLearning, Megan Othus, 411214

Discussion

ESH eLearning, Faculty / Presenters, 411212

CON

ESH eLearning, Charles Craddock, 411211

Introduction

ESH eLearning, Jordi Esteve, 411209

Panel discussion

ESH eLearning, Faculty / Presenters, 411208

Case-based lecture: Post remission treatment in MRD-negative intermediate risk AML

ESH eLearning, Adriano Venditti, 411207

Case-based lecture: Management of FL3+AML after allo HCT

ESH eLearning, Alexander Perl, 411206

Case-based Lecture: What to do with TP53-mut AML?

ESH eLearning, David Sallman, 411205

Interactive case: Relapse after VenAza

ESH eLearning, Lionel Adès, 411204

Satellite Symposium: Interactive case studies for an IDH1 mutated patient ineligible for intensive chemotherapy - From diagnosis to treatment

ESH eLearning, Faculty / Presenters, 411203